Beta Bionics, Inc.

Beta Bionics, Inc. (BBNX) priced its initial public offering on Jan 31, 2025 at $17.00 per share, within its $16.00–$17.00 range, raising $204M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $728.6M. BofA Securities was lead-left underwriter, joined by Piper Sandler, Leerink Partners and Stifel and others. Cooley and Whalen advised the company and Latham & Watkins advised the underwriters.

Beta Bionics, Inc. is a commercial-stage medical device company developing solutions for insulin-requiring people with diabetes. Its iLet Bionic Pancreas is a device cleared by the FDA that uses adaptive closed-loop algorithms to determine insulin doses.

Status

IPO

Ticker

BBNX

Exchange

Nasdaq Global Market

Priced

Jan 31, 2025

IPO price

$17.00

Price range

$16.00–$17.00

Raised

$204M

Market cap at IPO price

$728.6M

First filed

Jan 6, 2025

Underwriters

BofA Securities, Piper Sandler, Leerink Partners, Stifel and Lake Street

Company counsel

Cooley and Whalen

Underwriters' counsel

Latham & Watkins

Sector

Healthcare

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.